Chemistry:DOV-216,303
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H11Cl2N |
| Molar mass | 228.12 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and DOV terminated their relationship in December 2006.[2]:12[3]
It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]
As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]:6
In a mouse model, DOV-216,303 has shown the ability to promote recovery after spinal cord contusion.[5]
See also
References
- ↑ McCoy, Michael (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". Chemical & Engineering News. http://pubs.acs.org/cen/news/8232/8232earlybuscon2.html.
- ↑ 2.0 2.1 "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008. https://www.sec.gov/Archives/edgar/data/1066833/000114420408019048/v108269_10k.htm. "DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned."
- ↑ "DOV 216303" (in en). Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800017554.
- ↑ 4.0 4.1 "Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor". CNS Drug Reviews 12 (2): 123–34. 2006. doi:10.1111/j.1527-3458.2006.00123.x. PMID 16958986.
- ↑ "The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice". Neuroscience Letters 675: 1–6. May 2018. doi:10.1016/j.neulet.2018.03.050. PMID 29578004.
 |  |
